For research use only. Not for therapeutic Use.
Irinotecan hydrochloride trihydrate (Cat No.:I007360) is an antineoplastic drug used in the treatment of various types of cancer, particularly colorectal cancer. It is a water-soluble prodrug that is converted in the body to its active metabolite, SN-38, by carboxylesterase enzymes. SN-38 inhibits topoisomerase I, an enzyme involved in DNA replication and repair, leading to DNA damage and cell death. Irinotecan hydrochloride trihydrate has demonstrated efficacy against solid tumors and is commonly used in combination chemotherapy regimens. It has shown benefits in both first-line and second-line treatments for colorectal cancer, as well as other malignancies such as small-cell lung cancer and pancreatic cancer.
| Catalog Number | I007360 |
| CAS Number | 136572-09-3 |
| Synonyms | CPT11; CPT-11; CPT 11; U101440E; HSDB 7607; HSDB-7607; HSDB7607; camptothecin-11; irinotecan; irinotecan HCl; Bbrand name: Camptosa; Campto.;(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3/’,4/’:6,7]indolizino[1,2-b]quinolin-9- |
| Molecular Formula | C33H45ClN4O9 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| Overview of Clinical Research | Irinotecan hydrochloride is a DNA topoisomerase I inhibitor. The phase I study for pancreatic cancer is ongoing in China. |
| IUPAC Name | [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;trihydrate;hydrochloride |
| InChI | InChI=1S/C33H38N4O6.ClH.3H2O/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;;;;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H;3*1H2/t33-;;;;/m0..../s1 |
| InChIKey | KLEAIHJJLUAXIQ-JDRGBKBRSA-N |
| SMILES | O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O) =C7C=C65)=O)=C(CC)C4=C3.[H]Cl.[H]O[H].[H]O[H].[H]O[H] |
| Reference | 1: Goto A. [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:125-30. Review. Japanese. PubMed PMID: 16897987.<br /> |
